Giant Biogene Holding Co., Ltd. (HKG:2367) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
Giant Biogene Holding Co., Ltd. (HKG:2367) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
It is hard to get excited after looking at Giant Biogene Holding's (HKG:2367) recent performance, when its stock has declined 8.7% over the past three months. However, stock prices are usually driven by a company's financial performance over the long term, which in this case looks quite promising. Specifically, we decided to study Giant Biogene Holding's ROE in this article.
看着巨人生物控股公司(HKG: 2367)最近的表現,很難感到興奮,當時該公司的股票在過去三個月中下跌了8.7%。但是,股票價格通常由公司的長期財務業績驅動,在這種情況下,這看起來很有希望。具體而言,我們決定在本文中研究巨人生物控股公司的投資回報率。
Return on Equity or ROE is a test of how effectively a company is growing its value and managing investors' money. In short, ROE shows the profit each dollar generates with respect to its shareholder investments.
股本回報率或投資回報率是對公司增值和管理投資者資金的有效性的考驗。簡而言之,投資回報率顯示了每美元從其股東投資中產生的利潤。
View our latest analysis for Giant Biogene Holding
查看我們對巨人生物控股公司的最新分析
How Is ROE Calculated?
ROE 是如何計算的?
The formula for return on equity is:
股本回報率的公式是:
Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity
股本回報率 = 淨利潤(來自持續經營業務)÷ 股東權益
So, based on the above formula, the ROE for Giant Biogene Holding is:
因此,根據上述公式,Giant Biogene Holdings的投資回報率爲:
35% = CN¥1.2b ÷ CN¥3.5b (Based on the trailing twelve months to June 2023).
35% = 1.2億元人民幣 ¥35億元人民幣(基於截至2023年6月的過去十二個月)。
The 'return' is the amount earned after tax over the last twelve months. Another way to think of that is that for every HK$1 worth of equity, the company was able to earn HK$0.35 in profit.
“申報表” 是過去十二個月的稅後收入金額。另一種思考方式是,每持有價值1港元的股權,該公司就能賺取0.35港元的利潤。
What Is The Relationship Between ROE And Earnings Growth?
投資回報率與收益增長之間有什麼關係?
We have already established that ROE serves as an efficient profit-generating gauge for a company's future earnings. Depending on how much of these profits the company reinvests or "retains", and how effectively it does so, we are then able to assess a company's earnings growth potential. Assuming all else is equal, companies that have both a higher return on equity and higher profit retention are usually the ones that have a higher growth rate when compared to companies that don't have the same features.
我們已經確定,投資回報率是衡量公司未來收益的有效盈利指標。然後,我們能夠評估公司的收益增長潛力,具體取決於公司對這些利潤進行再投資或 “保留” 了多少及其有效性。假設其他條件都一樣,與功能不相同的公司相比,具有更高股本回報率和更高利潤保留率的公司通常具有更高的增長率。
Giant Biogene Holding's Earnings Growth And 35% ROE
巨人生物基因控股公司的收益增長和35%的投資回報率
To begin with, Giant Biogene Holding has a pretty high ROE which is interesting. Second, a comparison with the average ROE reported by the industry of 8.3% also doesn't go unnoticed by us. This likely paved the way for the modest 11% net income growth seen by Giant Biogene Holding over the past five years.
首先,Giant Biogene Holding的投資回報率相當高,這很有趣。其次,與該行業報告的8.3%的平均投資回報率進行比較也不會被我們忽視。這可能爲Giant Biogene Holding在過去五年中實現11%的溫和淨收入增長鋪平了道路。
Next, on comparing with the industry net income growth, we found that Giant Biogene Holding's growth is quite high when compared to the industry average growth of 8.8% in the same period, which is great to see.
接下來,與行業淨收入增長相比,我們發現巨人生物控股公司的增長相當高,而同期的行業平均增長率爲8.8%,這很高興看到。
![past-earnings-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20231210/0-ead99012b75ac7ff6dc5444a63e66b7e-0-35fb9d61fde395f57c72a63a2e2dcb91.png/big)
The basis for attaching value to a company is, to a great extent, tied to its earnings growth. It's important for an investor to know whether the market has priced in the company's expected earnings growth (or decline). Doing so will help them establish if the stock's future looks promising or ominous. What is 2367 worth today? The intrinsic value infographic in our free research report helps visualize whether 2367 is currently mispriced by the market.
賦予公司價值的基礎在很大程度上與其收益增長息息相關。對於投資者來說,重要的是要知道市場是否影響了公司的預期收益增長(或下降)。這樣做將幫助他們確定股票的未來是光明還是不祥。今天的2367值多少錢?我們的免費研究報告中的內在價值信息圖有助於直觀地了解市場目前是否對2367進行了錯誤的定價。
Is Giant Biogene Holding Using Its Retained Earnings Effectively?
Giant Biogene Holding是否有效地使用其留存收益?
Giant Biogene Holding doesn't pay any dividend, meaning that all of its profits are being reinvested in the business, which explains the fair bit of earnings growth the company has seen.
巨頭Biogene Holding不支付任何股息,這意味着其所有利潤都將再投資於該業務,這解釋了該公司的收益增長幅度。
Summary
摘要
On the whole, we feel that Giant Biogene Holding's performance has been quite good. Particularly, we like that the company is reinvesting heavily into its business, and at a high rate of return. Unsurprisingly, this has led to an impressive earnings growth. Having said that, looking at the current analyst estimates, we found that the company's earnings are expected to gain momentum. To know more about the company's future earnings growth forecasts take a look at this free report on analyst forecasts for the company to find out more.
總體而言,我們認爲Giant Biogene Holding的表現相當不錯。特別是,我們喜歡該公司對其業務進行大量再投資,而且回報率很高。毫不奇怪,這帶來了可觀的收益增長。話雖如此,從分析師目前的估計來看,我們發現該公司的收益有望增強。要了解有關公司未來收益增長預測的更多信息,請查看這份關於分析師對公司的預測的免費報告,以了解更多信息。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。